AtriCure Reports Third Quarter 2023 Financial Results

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2023 financial results.

“We are excited to report another strong quarter at AtriCure, driven by the performance across our business globally. We also made progress against many strategic initiatives in our pillars of innovation, education and clinical science,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “To that end, we continue to prioritize thoughtful investments while demonstrating meaningful operating leverage in our business. As we look to the future, we remain confident in the vast potential of our markets and our ability to deliver profitable growth.”

Third Quarter 2023 Financial Results

Revenue for the third quarter 2023 was $98.3 million, an increase of 18.1% over third quarter 2022 revenue (17.3% on a constant currency basis). Our worldwide revenue growth reflects continuing adoption of our products by physicians for the treatment of patients with Afib, LAA management and post-operative pain management.

U.S. revenue was $81.7 million, an increase of $11.9 million or 17.1%, compared to the third quarter 2022. U.S. revenue growth was driven by sales across product lines, highlighted by sales of the EnCompass clamp in open ablation, cryoSPHERE probe for post-operative pain management and the AtriClip Flex·V device in appendage management. International revenue increased $3.1 million or 23.2% (18.7% on a constant currency basis) to $16.6 million, across all franchises and geographic regions. On a sequential basis, worldwide revenue for the third quarter 2023 decreased approximately 2.6% from the second quarter 2023 due to normal seasonality of procedures in summer months.

Gross profit for the third quarter 2023 was $73.9 million compared to $61.7 million for the third quarter 2022. Gross margin was 75.2% for the third quarter 2023, showing improvement of 110 basis points from the third quarter 2022. The current quarter reflects leverage of our operations and production efficiencies, partially offset by pressure from geographic and product mix. Loss from operations for the third quarter 2023 was $8.1 million, compared to $10.7 million for the third quarter 2022, reflecting strong revenue growth, cost efficiencies, and improving operating leverage. Basic and diluted net loss per share was $0.20 for the third quarter 2023, compared to $0.27 for the third quarter 2022.

Adjusted EBITDA was positive for the third quarter 2023 at $4.7 million, compared to negative $0.7 million for third quarter of 2022. Adjusted loss per share for the third quarter 2023 was $0.20, compared to $0.27 for the third quarter 2022.

Constant currency revenue, adjusted EBITDA and adjusted loss per share are non-GAAP measures. We discuss these non-GAAP measures and provide reconciliations to GAAP measures later in this release.

2023 Financial Guidance

Full year 2023 revenue is projected to be $394 million to $396 million, reflecting growth of approximately 19% to 20% over full year 2022. Management now expects full year 2023 positive adjusted EBITDA of approximately $18 million to $20 million, and full year 2023 adjusted loss per share of approximately $0.74 to $0.76.

Conference Call

AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, November 1, 2023 to discuss third quarter 2023 financial results. To access the webcast, please visit the Investors page of AtriCure’s corporate website at https://ir.atricure.com/events-and-presentations/events. Participants are encouraged to register more than 15 minutes before the webcast start time. A replay of the presentation will be available for 90 days following the presentation.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator Synergy Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

Forward-Looking Statements

This press release contains “forward-looking statements”– that is, statements related to future events that by their nature address matters that are uncertain. This press release also includes forward-looking projected financial information that is based on current estimates and forecasts. Actual results could differ materially. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, visit http://www.atricure.com/forward-looking-statements as well as our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q which contain risk factors. Except where otherwise noted, the information contained in this release is as of November 1, 2023. We assume no obligation to update any forward-looking statements contained in this release as a result of new information or future events or developments, except as may be required by law.

Use of Non-GAAP Financial Measures

To supplement AtriCure’s condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, AtriCure provides certain non-GAAP financial measures in this release as supplemental financial metrics.

Revenue reported on a constant currency basis is a non-GAAP measure, calculated by applying previous period foreign currency exchange rates to each of the comparable periods. Management analyzes revenue on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on revenue, the Company believes that evaluating growth in revenue on a constant currency basis provides an additional and meaningful assessment of revenue to both management and investors.

Adjusted EBITDA is calculated as net loss before other income/expense (including interest), income tax expense, depreciation and amortization expense, share-based compensation expense, acquisition costs, legal settlements, impairment of intangible assets and change in fair value of contingent consideration liabilities. Management believes in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. The excluded items vary in frequency and/or impact on our continuing results of operations and management believes that the excluded items are typically not reflective of our ongoing core business operations and financial condition. Further, management uses adjusted EBITDA for both strategic and annual operating planning. A reconciliation of adjusted EBITDA reported in this release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of Non-GAAP Adjusted Income (Loss) (Adjusted EBITDA)” later in this release.

Adjusted loss per share is a non-GAAP measure which calculates the net loss per share before non-cash adjustments in fair value of contingent consideration liabilities, impairment of intangible assets and legal settlements. A reconciliation of adjusted loss income per share reported in this release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of Non-GAAP Adjusted Loss Per Share” later in this release.

The non-GAAP financial measures used by AtriCure may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for AtriCure’s financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financials measures included in this press release, and not to rely on any single financial measure to evaluate our business.

ATRICURE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In Thousands, Except Per Share Amounts) (Unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
	2023				2022				2023				2022
United States Revenue:
Open ablation	$	25,844			$	21,569			$	77,988			$	62,613
Minimally invasive ablation		10,893				10,077				31,900				28,846
Pain management		12,591				10,510				36,249				28,734
Total ablation		49,328				42,156				146,137				120,193
Appendage management		32,364				27,620				98,647				83,120
Total United States		81,692				69,776				244,784				203,313
International Revenue:
Open ablation		8,007				6,680				23,015				19,385
Minimally invasive ablation		1,578				1,445				4,820				4,249
Pain management		547				121				1,214				375
Total ablation		10,132				8,246				29,049				24,009
Appendage management		6,466				5,224				18,869				15,029
Total International		16,598				13,470				47,918				39,038
Total revenue		98,290				83,246				292,702				242,351
Cost of revenue		24,421				21,533				72,147				61,524
Gross profit		73,869				61,713				220,555				180,827
Operating expenses:
Research and development expenses		20,354				15,169				53,119				43,589
Selling, general and administrative expenses		61,604				57,267				185,451				175,771
Total operating expenses		81,958				72,436				238,570				219,360
Loss from operations		(8,089	)			(10,723	)			(18,015	)			(38,533	)
Other expense, net		(919	)			(1,503	)			(2,416	)			(3,616	)
Loss before income tax expense		(9,008	)			(12,226	)			(20,431	)			(42,149	)
Income tax expense		47				46				218				147
Net loss	$	(9,055	)		$	(12,272	)		$	(20,649	)		$	(42,296	)
Basic and diluted net loss per share	$	(0.20	)		$	(0.27	)		$	(0.45	)		$	(0.93	)
Weighted average shares used in computing net loss per share:
Basic and diluted		46,411				45,823				46,262				45,682

ATRICURE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In Thousands) (Unaudited)
	September 30, 2023				December 31, 2022
Assets
Current assets:
Cash, cash equivalents, and short-term investments	$	133,014			$	121,113
Accounts receivable, net		51,528				42,693
Inventories		61,894				45,931
Prepaid and other current assets		6,283				5,477
Total current assets		252,719				215,214
Long-term investments		—				51,509
Property and equipment, net		41,400				38,833
Operating lease right-of-use assets		4,043				3,787
Goodwill and intangible assets, net		300,465				274,120
Other noncurrent assets		1,644				1,985
Total assets	$	600,271			$	585,448
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued liabilities	$	61,836			$	52,920
Current maturities of debt and leases		20,702				5,472
Total current liabilities		82,538				58,392
Long-term debt		42,153				56,834
Finance and operating lease liabilities		11,520				12,242
Other noncurrent liabilities		1,227				1,226
Total liabilities		137,438				128,694
Stockholders' equity:
Common stock		47				47
Additional paid-in capital		812,238				787,422
Accumulated other comprehensive loss		(2,184	)			(4,096	)
Accumulated deficit		(347,268	)			(326,619	)
Total stockholders' equity		462,833				456,754
Total liabilities and stockholders' equity	$	600,271			$	585,448

ATRICURE, INC. AND SUBSIDIARIES RECONCILIATION OF GAAP RESULTS TO NON-GAAP RESULTS (In Thousands) (Unaudited)   Reconciliation of Non-GAAP Adjusted Income (Loss) (Adjusted EBITDA)
	Three Months Ended September 30,								Nine Months Ended September 30,
	2023				2022				2023				2022
Net loss, as reported	$	(9,055	)		$	(12,272	)		$	(20,649	)		$	(42,296	)
Income tax expense		47				46				218				147
Other expense, net		919				1,503				2,416				3,616
Depreciation and amortization expense		4,111				2,987				10,634				8,791
Share-based compensation expense		8,661				7,001				26,416				21,574
Net gain from legal settlements		—				—				(4,412	)			—
Non-GAAP adjusted income (loss) (adjusted EBITDA)	$	4,683			$	(735	)		$	14,623			$	(8,168	)

Reconciliation of Non-GAAP Adjusted Loss Per Share
	Three Months Ended September 30,								Nine Months Ended September 30,
	2023				2022				2023				2022
Net loss, as reported	$	(9,055	)		$	(12,272	)		$	(20,649	)		$	(42,296	)
Net gain from legal settlements		—				—				(4,412	)			—
Non-GAAP adjusted net loss	$	(9,055	)		$	(12,272	)		$	(25,061	)		$	(42,296	)
Basic and diluted adjusted net loss per share	$	(0.20	)		$	(0.27	)		$	(0.54	)		$	(0.93	)
Weighted average shares used in computing adjusted net loss per share
Basic and diluted		46,411				45,823				46,262				45,682

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20231101605552/en/

The AtriCure Stock at the time of publication of the news with a raise of +1,33 % to 35,10USD on Nasdaq stock exchange (01. November 2023, 20:51 Uhr).